Gerald Berry

Publication Details

• Sirolimus (rapamycin) monotherapy prevents graft vascular disease in nonhuman primate recipients of orthotopic aortic allografts.

  Dambrin C, Klupp J, Bîrsan T, Luna J, Suzuki T, Lam T, Stähr P, Hausen B, Christians U, Fitzgerald P, Berry G, Morris R. Circulation. 2003; 107 (18): 2369-74

  Delayed treatment with sirolimus (SRL) halts progression of graft vascular disease (GVD) in nonhuman primate (NHP) aortic allograft recipients. In this study, we investigated whether SRL monotherapy prevents the development of GVD.

  PubMedID: 12719285